Yadav S, Sharma P, Zakalik D (2018) Comparison of Demographics, Tumor Characteristics, and Survival Between Pancreatic Adenocarcinomas and Pancreatic Neuroendocrine Tumors: A Population-based Study. Am J Clin Oncol 41:485-491. https://doi.org/10.1097/COC.0000000000000305

Article  PubMed  Google Scholar 

Sonbol MB, Mazza GL, Mi L, Oliver T, Starr J, Gudmundsdottir H, et al (2022) Survival and Incidence Patterns of Pancreatic Neuroendocrine Tumors Over the Last 2 Decades: A SEER Database Analysis. Oncologist 27:573-578. https://doi.org/10.1093/oncolo/oyac049

Article  PubMed  PubMed Central  Google Scholar 

Halfdanarson TR, Rabe KG, Rubin J, Petersen GM (2008) Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 19:1727-1733. https://doi.org/10.1093/annonc/mdn351

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hofland J, Refardt JC, Feelders RA, Christ E, de Herder WW (2024) Approach to the Patient: Insulinoma. J Clin Endocrinol Metab 109:1109-18. https://doi.org/10.1210/clinem/dgad641

Article  PubMed  Google Scholar 

Kos-Kudła B, Castaño JP, Denecke T, Grande E, Kjaer A, Koumarianou A, et al (2023) European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol 35:e13343. https://doi.org/10.1111/jne.13343

Article  CAS  PubMed  Google Scholar 

Hofland J, Falconi M, Christ E, Castaño JP, Faggiano A, Lamarca A, et al (2023) European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol 35:e13318. https://doi.org/10.1111/jne.13318

Article  CAS  PubMed  Google Scholar 

Keutgen XM, Nilubol N, Kebebew E (2016) Malignant-functioning neuroendocrine tumors of the pancreas: A survival analysis. Surgery 159:1382-1389. https://doi.org/10.1016/j.surg.2015.11.010

Article  PubMed  Google Scholar 

Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O’Dorisio TM, et al (2020) The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas 49:863-881. https://doi.org/10.1097/MPA.0000000000001597

Article  PubMed  Google Scholar 

Yu R, Nissen NN, Hendifar A, Tang L, Song YL, Chen YJ, et al (2017) A Clinicopathological Study of Malignant Insulinoma in a Contemporary Series. Pancreas 46:48-56. https://doi.org/10.1097/MPA.0000000000000718

Article  CAS  PubMed  Google Scholar 

Hackeng WM, Brosens LAA, Dreijerink KMA (2023) Aggressive versus indolent insulinomas: new clinicopathological insights. Endocr Relat Cancer 30: e220321. https://doi.org/10.1530/ERC-22-0321

Article  PubMed  Google Scholar 

Hirshberg B, Cochran C, Skarulis MC, Libutti SK, Alexander HR, Wood BJ, et al (2005) Malignant insulinoma: spectrum of unusual clinical features. Cancer 104:264-272. https://doi.org/10.1002/cncr.21179

Article  PubMed  Google Scholar 

Preston CA, Sachithanandan N, Sim IW, van Heerden J, Farrell S (2024) Insulinoma: Metastatic Recurrence 38 Years Following Initial Diagnosis in Pregnancy. JCEM Case Rep 2:luad168. https://doi.org/10.1210/jcemcr/luad168

Article  PubMed  PubMed Central  Google Scholar 

Yu J, Ping F, Zhang H, Li W, Yuan T, Fu Y, et al (2018) Clinical Management of Malignant Insulinoma: a single Institution’s experience over three decades. BMC Endocr Disord 18:92. https://doi.org/10.1186/s12902-018-0321-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gonzalez-Gonzalez A, Recio-Cordova JM (2006) Liver metastases 9 years after removal of a malignant insulinoma which was initially considered benign. JOP 7:226-229.

PubMed  Google Scholar 

Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, et al (2011) DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331:1199-1203. https://doi.org/10.1126/science.1200609

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heaphy CM, Singhi AD (2022) The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors. Hum Pathol 129:11-20. https://doi.org/10.1016/j.humpath.2022.07.015

Article  CAS  PubMed  Google Scholar 

Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, et al (2011) Altered telomeres in tumors with ATRX and DAXX mutations. Science 333:425. https://doi.org/10.1126/science.1207313

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, et al (2017) Whole-genome landscape of pancreatic neuroendocrine tumours. Nature 543:65-71. https://doi.org/10.1038/nature21063

Article  CAS  PubMed  Google Scholar 

Marinoni I, Kurrer AS, Vassella E, Dettmer M, Rudolph T, Banz V, et al (2014) Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 146:453-60.e5. https://doi.org/10.1053/j.gastro.2013.10.020

Article  CAS  PubMed  Google Scholar 

Dyer MA, Qadeer ZA, Valle-Garcia D, Bernstein E. (2017) ATRX and DAXX: Mechanisms and Mutations. Cold Spring Harb Perspect Med 7:a026567. https://doi.org/10.1101/cshperspect.a026567.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goldberg AD, Banaszynski LA, Noh KM, Lewis PW, Elsaesser SJ, Stadler S, et al (2010) Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 140:678-691. https://doi.org/10.1016/j.cell.2010.01.003

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drané P, Ouararhni K, Depaux A, Shuaib M, Hamiche A (2010) The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes Dev 24:1253-1265. https://doi.org/10.1101/gad.566910

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mori JO, Keegan J, Flynn RL, Heaphy CM (2024) Alternative lengthening of telomeres: mechanism and the pathogenesis of cancer. J Clin Pathol 77:82-86. https://doi.org/10.1136/jcp-2023-209005

Article  PubMed  Google Scholar 

Dreijerink KM, Hackeng WM, Singhi AD, Heaphy CM, Brosens LA (2022) Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors. J Pathol 256:143-148. https://doi.org/10.1002/path.5834

Article  CAS  PubMed  Google Scholar 

Ueda H, Akiyama Y, Shimada S, Mogushi K, Serizawa M, Matsumura S, et al (2018) Tumor suppressor functions of DAXX through histone H3.3/H3K9me3 pathway in pancreatic NETs. Endocr Relat Cancer 25:619-631. https://doi.org/10.1530/ERC-17-0328

Article  CAS  PubMed  Google Scholar 

Pang Y, Chen X, Ji T, Cheng M, Wang R, Zhang C, et al (2023) The Chromatin Remodeler ATRX: Role and Mechanism in Biology and Cancer. Cancers (Basel)15:2228. https://doi.org/10.3390/cancers15082228

Article  CAS  PubMed  Google Scholar 

Kim JY, Brosnan-Cashman JA, An S, Kim SJ, Song KB, Kim MS, et al (2017) Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival. Clin Cancer Res 23:1598-1606. https://doi.org/10.1158/1078-0432.CCR-16-1147

Article  CAS  PubMed  Google Scholar 

Hackeng WM, Brosens LAA, Kim JY, O’Sullivan R, Sung YN, Liu TC, et al (2021) Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut 71:961-973. https://doi.org/10.1136/gutjnl-2020-322595

Article  CAS